Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 20/20 | 0.61 |
| ▸ | MAOA | P21397 | 7/20 | 0.58 |
| ▸ | MAOB | P27338 | 7/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2406448 | 1.00 | KDM1A (0.61) | KDM1AMAOAMAOB | |
| SCHEMBL3265783 | 0.78 | KDM1A (0.63) | KDM1AMAOAMAOB | |
| SCHEMBL240579 | 0.78 | KDM1A (0.63) | KDM1AMAOAMAOB | |
| SCHEMBL240580 | 0.78 | KDM1A (0.63) | KDM1AMAOAMAOB | |
| SCHEMBL3269362 | 0.76 | KDM1A (1.00) | KDM1AMAOAMAOB | |
| SCHEMBL238912 | 0.76 | KDM1A (1.00) | KDM1AMAOAMAOB | |
| SCHEMBL238911 | 0.76 | KDM1A (1.00) | KDM1AMAOAMAOB | |
| SCHEMBL4145762 | 0.74 | KDM1A (1.00) | KDM1AMAOAMAOB | |
| SCHEMBL4145760 | 0.74 | KDM1A (1.00) | KDM1AMAOAMAOB | |
| SCHEMBL238117 | 0.73 | KDM1A (0.62) | KDM1AMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9616058-B2 | Potent selective LSD1 inhibitors and dual LSD1/MAO-B inhibitors for antiviral use | ORYZON GENOMICS, S.A. (ES) | 2017-04-11 | — | — | US | claimed |
| US-9186337-B2 | Lysine demethylase inhibitors for diseases and disorders associated with Hepadnaviridae | ORYZON GENOMICS S.A. (ES) | 2015-11-17 | — | — | US | claimed |
| EP-3013424-B1 | LSD INHIBITORS FOR MODULATING CANCER STEM CELLS | EPIAXIS THERAPEUTICS PTY LTD (AU) | 2024-09-25 | — | — | EP | disclosed |
| WO-2021195723-A1 | \"METHODS FOR TREATMENT OF CORONAVIRUS INFECTIONS\ | THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH (AU) | 2021-10-07 | — | — | WO | disclosed |
| US-20210186905-A1 | ENHANCING T-CELL FUNCTION AND TREATING A T-CELL DYSFUNCTIONAL DISORDER WITH A COMBINATION OF AN LSD INHIBITOR AND A PD-1 BINDING ANTAGONIST | EPIAXIS THERAPEUTICS PTY LTD (AU) | 2021-06-24 | — | — | US | disclosed |
| US-20210121496-A1 | METHODS AND COMPOSITIONS FOR MODULATING CANCER STEM CELLS | EpiAxis Therapeutics Pty Ltd. (AU) | 2021-04-29 | — | — | US | disclosed |
| EP-3716963-A1 | ENHANCING T-CELL FUNCTION AND TREATING A T-CELL DYSFUNCTIONAL DISORDER WITH A COMBINATION OF AN LSD INHIBITOR AND A PD1 BINDING ANTAGONIST | Epiaxis Therapeutics Pty Ltd (AU) | 2020-10-07 | — | — | EP | disclosed |
| US-20200289437-A1 | Compositions for Modulating Cancer Stem Cells and Uses Therefor | EpiAxis Therapeutics Pty Ltd. (AU) | 2020-09-17 | — | — | US | disclosed |
| CN-111655247-A | Enhancing T cell function and treating T cell dysfunction disorders with a combination of a LSD inhibitor and a PD1 binding antagonist | 艾比克斯治疗私人有限公司 | 2020-09-11 | — | — | CN | disclosed |
| US-20190262377-A1 | METHODS AND COMPOSITIONS FOR MODULATING CANCER STEM CELLS | EpiAxis Therapeutics Pty Ltd. (AU) | 2019-08-29 | — | — | US | disclosed |
| US-10220053-B2 | Methods and compositions for modulating cancer stem cells | UNIVERSITY OF CANBERRA (AU) | 2019-03-05 | — | — | US | disclosed |
| US-9616058-B2 | Potent selective LSD1 inhibitors and dual LSD1/MAO-B inhibitors for antiviral use | ORYZON GENOMICS, S.A. (ES) | 2017-04-11 | — | — | US | disclosed |
| US-20160143938-A1 | Methods and compositions for modulating cancer stem cells | EpiAxis Therapeutics Pty Ltd. (AU) | 2016-05-26 | — | — | US | disclosed |
| EP-3013424-A1 | METHODS AND COMPOSITIONS FOR MODULATING CANCER STEM CELLS | University of Canberra (AU) | 2016-05-04 | — | — | EP | disclosed |
| US-9186337-B2 | Lysine demethylase inhibitors for diseases and disorders associated with Hepadnaviridae | ORYZON GENOMICS S.A. (ES) | 2015-11-17 | — | — | US | disclosed |
| WO-2014205511-A1 | METHODS AND COMPOSITIONS FOR MODULATING CANCER STEM CELLS | UNIVERSITY OF CANBERRA (AU) | 2014-12-31 | — | — | WO | disclosed |
| US-20130274267-A1 | INHIBITORS FOR ANTIVIRAL USE | ORYZON GENOMICS, S.A. (ES) | 2013-10-17 | — | — | US | disclosed |
| US-20130095067-A1 | LYSINE DEMETHYLASE INHIBITORS FOR DISEASES AND DISORDERS ASSOCIATED WITH HEPADNAVIRIDAE | ORYZON GENOMICS, S.A. (ES) | 2013-04-18 | — | — | US | disclosed |
| WO-2011106106-A2 | LYSINE DEMETHYLASE INHIBITORS FOR DISEASES AND DISORDERS ASSOCIATED WITH HEPADNAVIRIDAE | ORYZON GENOMICS, S.A. (ES) | 2011-09-01 | — | — | WO | disclosed |
| WO-2011106573-A2 | LYSINE DEMETHYLASE INHIBITORS FOR DISEASES AND DISORDERS ASSOCIATED WITH HEPADNAVIRIDAE | ORYZON GENOMICS, S.A. (ES) | 2011-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190262377-A1 | METHODS AND COMPOSITIONS FOR MODULATING CANCER STEM CELLS | BMI1, KDM1B, KDM6B | KDM1A 6/4885MAOA 3132/4885MAOB 2932/4885 |
| US-20160143938-A1 | Methods and compositions for modulating cancer stem cells | BMI1, KDM1B, KDM6B | KDM1A 6/4885MAOA 3132/4885MAOB 2932/4885 |
| US-10220053-B2 | Methods and compositions for modulating cancer stem cells | BMI1, KDM1B, KDM6B | KDM1A 6/4885MAOA 3132/4885MAOB 2932/4885 |
| US-20210186905-A1 | ENHANCING T-CELL FUNCTION AND TREATING A T-CELL DYSFUNCTIONAL DISORDER WITH A COMBINATION OF AN LSD INHIBITOR AND A PD-1 BINDING ANTAGONIST | PDCD1, CD274, PDCD1LG2 | KDM1A 8/4885MAOA 54/4885MAOB 36/4885 |
| US-20200289437-A1 | Compositions for Modulating Cancer Stem Cells and Uses Therefor | PRKCQ, PRKCG, PRKCH | KDM1A 44/4885MAOA 2357/4885MAOB 2259/4885 |
| US-20130095067-A1 | LYSINE DEMETHYLASE INHIBITORS FOR DISEASES AND DISORDERS ASSOCIATED WITH HEPADNAVIRIDAE | KDM1A, KDM1B, KDM2A | KDM1A 1/4885MAOA 683/4885MAOB 685/4885 |
| US-20130274267-A1 | INHIBITORS FOR ANTIVIRAL USE | MAOB, KDM1B, KDM2B | KDM1A 14/4885MAOA 11/4885MAOB 1/4885 |
| US-20210121496-A1 | METHODS AND COMPOSITIONS FOR MODULATING CANCER STEM CELLS | BMI1, KDM1B, KDM6B | KDM1A 6/4885MAOA 3132/4885MAOB 2932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.